article Open AccessTop 1% cited

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

New England Journal of Medicine · 2015 · Vol. 373(2) · pp. 123–135

Julie R. Brahmer✉(Heidelberg University)Karen L. Reckamp(City of Hope)Paul Baas(The Netherlands Cancer Institute)Lucio Crinò(University of Perugia)Wilfried Eberhardt(Ruhrlandklinik)Elena Poddubskaya(Russian Cancer Research Center NN Blokhin)Scott Antonia(Moffitt Cancer Center)Adam Płużański(Centrum Onkologii)Everett E. Vokes(University of Chicago)Esther Holgado(Hospital Universitario HM Sanchinarro)David Waterhouse(Oncology Hematology Care)Neal Ready(Duke Medical Center)Justin F. Gainor(Massachusetts General Hospital)Osvaldo Arén Frontera(Centro de Estudios Científicos)Libor Havel(Fakultní nemocnice Bulovka)Martin Steins(Heidelberg University)Marina Chiara Garassino(Fondazione IRCCS Istituto Nazionale dei Tumori)Joachim G.J.V. Aerts(Amphia Ziekenhuis)Manuel Dómine(Hospital Universitario Fundación Jiménez Díaz)Luis Paz‐Ares(Hospital Universitario Virgen del Rocío)Martin Reck(LungenClinic Grosshansdorf)Christine Baudelet(Bristol-Myers Squibb (United States))Christopher Harbison(Bristol-Myers Squibb (United States))Brian Lestini(Bristol-Myers Squibb (United States))David R. Spigel(Sarah Cannon)

View via DOI Full-text PDF

Abstract

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research StudiesDocetaxelNivolumabMedicineHazard ratioInternal medicineLung cancerOncologyPopulationChemotherapyCancer

MeSH terms

DocetaxelNivolumabAdultAgedAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellFemaleHumansImmunoglobulin GLung NeoplasmsMaleMiddle AgedSurvival Analysis

Citations

8,491

FWCI

438.39

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer